Pelthos Therapeutics Inc. (PTHS)

Market Cap	10.68M
Revenue (ttm)	n/a
Net Income (ttm)	-7.36M
Shares Out	659.59K
EPS (ttm)	-12.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,513
Open	16.00
Previous Close	16.50
Day's Range	13.88 - 17.80
52-Week Range	4.50 - 38.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2025

About PTHS

Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body’s peripheral nervous system. The company’s lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both acute and chronic eye pain; and CT3000 to treat p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 11
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PTHS
• Website: https://channeltherapeutics.com